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2Abstract25
Infections of the human immunodeficiency virus (HIV) trigger host immune responses, but the virus can26
destroy the immune system and cause acquired immune deficiency syndrome (AIDS). Highly active27
antiretroviral therapy (HAART) can suppress viral replication and restore the impaired immune function. To28
understand HIV interactions with host immune cells during HAART, the transcriptomes of peripheral blood29
mononuclear cells (PBMC) from HIV patients and HIV negative volunteers before and two weeks after30
HAART initiation were analyzed using RNA sequencing (RNA-Seq) technology. Differentially expressed31
genes (DEGs) in response to HAART were firstly identified for each individual, then common features were32
extracted by comparing DEGs among individuals and finally HIV-related DEGs were obtained by33
comparing DEGs between the HIV patients and HIV negative volunteers. To demonstrate the power of this34
approach, minimum numbers of patients (one HIV alone; one HIV + tuberculosis, TB; one HIV+TB with35
immune reconstitution inflammatory syndrome during HAART) and two HIV negative volunteers were used.36
More than 15,000 gene transcripts were detected in each individual sample. Fourteen HAART up-regulated37
and eleven down-regulated DEGs were specifically identified in the HIV patients. Among them, nine38
up-regulated (CXCL1, S100P, AQP9, BASP1, MMP9, SOD2, LIMK2, IL1R2 and BCL2A1) and nine39
down-regulated DEGs (CD160, CD244, CX3CR1, IFIT1, IFI27, IFI44, IFI44L, MX1 and SIGLEC1) have40
already been reported as relevant to HIV infections in the literature, which demonstrates the credibility of41
the method. The newly identified HIV-related genes (up-regulated: ACSL1, GPR84, GPR97, ADM, LRG1;42
down-regulated: RASSF1, PATL2) were empirically validated using qRT-PCR. The Gene Set Enrichment43
Analysis (GSEA) was also used to determine pathways significantly affected by HAART. GSEA further44
confirmed the HAART relevance of five genes (ADM, AQP9, BASP1, IL1R2 and MMP9). The newly45
identified HIV-related genes, ADM (which encodes Adrenomedullin), a peptide hormone in circulation46
control, may contribute to HIV-associated hypertensions, providing new insights into HIV pathology and47
3novel strategies for developing anti-HIV target. More importantly, we demonstrated that comparative48
transcriptome analysis is a very powerful tool to identify infection related DEGs using a very small number49
of samples. This approach could be easily applied to improve the understanding of pathogen-host50
interactions in many infections and anti-infection treatments.51
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1.Introduction55
Human immunodeficiency virus-1 (HIV-1) is a retrovirus that primarily infects components of the56
human immune system, such as CD4+ T cells, macrophages and dendritic cells [1]. HIV directly and57
indirectly destroys CD4+ T cells, which leads to severe immunodeficiency and increased susceptibility to58
opportunistic infections in most infected patients [2]. In addition, HIV also induces chronic immune59
activation, including cells involved in the innate immunity and acquired immunity, not only during the early60
phases of the infection but also throughout the chronic phase [3]. The state of chronic immune activation61
contributes to the loss of CD4+ T cells and changes in the immune responses, ultimately leading to disease62
progression [4]. Highly active antiretroviral therapy (HAART) can suppress viral replication, reduce the63
virus load in a patient’s body and partially restore circulating CD4+ T cells to allow the immune system to64
combat HIV infections [5]. However, the side effects of this treatment may accumulate and problems65
including HIV-associated hypertension disorders[6] and cardiovascular disease[7] may emerge in certain66
patients during antiretroviral therapy (ART). Because an increasing number of patients suffer from drug67
toxicity, the emergence of drug resistant viruses and immune reconstitution inflammatory syndrome (IRIS)68
following the initiation of HAART represent new challenges in the battle against AIDS [8, 9].69
Genome-wide gene expression profiling is an informative method used to reveal global changes of the70
4immune system in health and/or disease conditions. It has been particularly useful in identifying biomarkers,71
examining disease states and investigating immune responses [10]. Although a number of transcriptomic72
studies of HIV infection have been conducted, most were based on microarray technologies that focused on73
a limited number of genes [11-15]. Thus, these methods are limited in their capacity to detect novel gene74
products that interact with the virus infection. Recently, next-generation sequencing (NGS) technology has75
provided a new methodology to both identify and quantify the gene transcripts detected in transcriptome76
studies [16]. This method, termed RNA-Seq (RNA sequencing), provides highly accurate measurements of77
genome-wide gene expression via high-throughput NGS sequencing and generates high quality78
transcriptomic data. This approach yields a plethora of information, including transcript abundance, gene79
structure, alternative splicing, profiles of non-coding RNA species and genetic polymorphisms [17-19].80
RNA-Seq has been applied in HIV-1 studies. For example, Stewart T. et al. used this technology to examine81
mRNA and MicroRNA changes in the transcriptome of CD4+ T cells infected with HIV in culture [20, 21].82
Ming D. et al. sequenced RNA transcripts in the brain of HIV-1 transgenic rats to identify differentially83
expressed genes (DEGs) and enriched pathways affected by the HIV transgene in different areas of the brain84
[22]. However, few studies have examined the utility of comparative transcriptomic analysis based on85
RNA-seq to investigate HIV-host interactions in samples from HIV patients, especially the transcriptional86
changes of host genes after HAART.87
Many genome-wide expression studies of HIV infection are based on an analysis of total peripheral88
blood mononuclear cells (PBMCs) [14, 23-25], which consist of over a dozen cell subsets, including T cells, B89
cells, NK cells and monocytes. Although the specific gene expression signals of particular cell subsets will90
be diluted by those from the other cells and thus reduce the specificity of this approach [12, 15, 21], PBMC91
is a good starting material to obtain generic information against HIV infection.92
In this study, we investigated changes in the transcriptomes of PBMCs from HIV positive patients and93
5HIV negative volunteers before and two weeks after HAART using RNA-Seq technology. To demonstrate94
the power of this approach, small cohorts (three HIV patients and two HIV negative volunteers) were used.95
We firstly identified the differentially expressed genes (DEGs) for the time course of each individual. The96
shared DEGs among individuals were then used to enable comparisons between the HIV patients and HIV97
negative volunteers. All DEGs were validated empirically by qRT-PCR. The Gene Set Enrichment Analysis98
(GSEA) was also used to identify pathways that were significantly affected by HAART. These analyses99
revealed new gene expression patterns of PBMCs and provided new insights into the pathogenesis of100
HIV-induced immune suppression and HIV-TB associated gene expression changes during HAART. Such101
an individual comparative transcriptome approach did not require large sample cohort thus could be valuable102
for future practice of precision medicine.103
104
2. Materials and Methods105
106
2.1.Ethics Statement107
The study protocol was approved by the Institutional Review Board of the Shenzhen Third People’s108
Hospital. Written informed consent was obtained from all participants.109
110
2.2.Treatment-naïve HIV infected and HIV negative individuals111
Three HIV-infected individuals and two HIV-negative volunteers were recruited at the Shenzhen Third112
People’s Hospital from April 2013 to September 2013 (Table 1). Two healthy persons who putatively113
exposed to HIV and proactively requested HAART were proved to be free of HIV infection by ELISA and114
HIV RNA testing one month later. All participants were screened for HIV antigens and antibodies via115
standard ELISA analyses, and these findings were further confirmed by Western Blotting. CD4 counts were116
6obtained by flow cytometry, and the viral loads were measured by qRT-PCR. Two of the three HIV117
serum-positive patients were also diagnosed as being positive for B. tuberculosis, as assessed by118
microbiology tests (sputum acid fast bacilli stain or cultures on Lowenstein–Jensen media). All clinical tests119
mentioned above were performed by the hospital clinical laboratory, which has a certified license issued by120
the National AIDS Reference Laboratory at China CDC.121
122
Treatment for the diagnosed HIV-TB patients consisted of standard fixed-dose chemotherapy for two123
weeks with isoniazid (H), ethambutol (E), rifampicin (R) and pyrazinamide (Z), followed by a combination124
of highly active antiretroviral therapy (HAART) and anti-TB treatment (HERZ) [26]. The HAART regimen125
consisted of zidovudine plus lamivudine with efavirenz, which is the recommended anti-HIV treatment126
regimen in China [27].127
128
2.3. Sample collection, PBMC isolation, RNA extraction and RNA-Seq129
sequencing130
In total, 10 blood samples (5 mL per sample) from five participants were collected at two different time131
points: immediately before and two-weeks after the start of HAART. The total RNA was extracted from132
each PBMC sample using the Qiagen RNeasy kit (QIAGEN). The RNA concentration and quality were133
measured using an Agilent 2100 Bioanalyzer (Agilent), and these analyses showed that all RNA samples134
had an RNA integrity number (RIN) of >7.5 and a 28S:18S rRNA ratio of >1.8. Beads containing oligo (dT)135
were used to isolate poly(A)-tailed mRNA from the total RNAs. The Purified mRNAs were used to136
construct RNA-Seq libraries, which were sequenced on an Illumina HiSeq 2000 sequencing platform (using137
TruSeqV3 sequencing reagents ) at the BGI-shenzhen (Expected library size: 200bp; Read length: 90 nt; and138
Sequencing strategy: paired-end sequencing) as described in previous article[28].139
7140
2.4.Mapping reads to the human genome and transcriptome database141
The reference sequences used in this study were the human genome and transcriptome sequences142
downloaded from the UCSC website (http://genome.ucsc.edu/index.html, version hg19). After the removal143
of low quality reads, clean reads were aligned to the reference genome or transcriptome using SOAP2 [29].144
No more than five mismatches were allowed in the alignment of each read.145
146
2.5. Normalization of gene and long non-coding RNA expression levels147
Reads that could be uniquely mapped to a reference gene were used to calculate the expression level.148
The gene expression level was measured based on the number of uniquely mapped reads per kilo-base of149
exon region per million mapped reads (RPKM). The formula is defined below:150 RPKM = 10଺CNL ÷ 10ଷ = C ∗ 10ଽN ∗ L
in which C is the number of reads uniquely mapped to the given gene; N is the number of reads uniquely151
mapped to all genes; L is the total length of exons from the given gene. For genes with more than one152
alternative transcript, the longest transcript was used to calculate the RPKM. The RPKM method eliminates153
the influence of different gene lengths and sequencing discrepancies on the gene expression calculation.154
Therefore, the RPKM value can be directly used to compare the differences in gene expression among155
samples. Based on RPKM, a global expression plot was produced to compare the expression profiles before156
and after HAART for each HIV-patient and HIV-negative volunteer.157
158
2.6. Principal Component Analysis (PCA)159
The R software (http://stat.ethz.ch/R-manual/R-patched/library/stats/html/prcomp.html), which is based on160
the RPKM value of each gene of the samples, was used to group and perform the PCA analysis of the161
8expression level with a cumulative proportion of principal component 1 (48.16%) and principal component162
2 (26.49%) of 0.75. A scatter figure was then drawn based on principal component 1 and principal163
component 2.164
165
2.7. Differentially expressed gene (DEG) analysis and Gene Ontology (GO)166
Enrichment167
Using the NOISeq program [30], we identified DEGs by comparing the expression level of the post-HAART168
sample to that of the pre-HAART sample from the same individual according to the following criteria and169
the DEG must meet condition: Probability>= 0.8 and fold change>=2. We then used the DAVID tools [31]170
to annotate and enrich the significant DEGs to certain Gene Ontology terms. The threshold for the GO171
enrichment analysis was an ease-score <=0.05 and p value < 0.05.172
173
2.8. Gene Set Enrichment Analysis174
Gene Set Enrichment Analysis (GSEA) is a computational method for association studies by examining175
whether the expression profile of a certain gene set have a significant tendency between two concerned176
biological states[32] (in this study, before and after HAART). Genes were ranked in descending order based177
on RPKM using the weighted log2 ratio of Classes metric. Nominal p values were calculated based on178
permutation tests using gene set permutation with 1000 permutations without balancing. The hallmark gene179
sets derived from the Molecular Signature Database (MSigDB) were selected for GSEA. Normalized180
enrichment scores were calculated as previously described using the GSEA software (version 2.2.0) and181
gene sets were ranked accordingly. False discovery rate (FDR) <0.05 was considered to be statistically182
significant.183
184
92.9. Quantitative real time PCR validations of differentially expressed genes185
To confirm the results obtained from the RNA-Seq analysis, we conducted quantitative real-time186
RT-PCR (qRT-PCR), the commonly used quantification method for studying gene expression. In brief, the187
total RNA from each sample was used for reverse transcription [33] with random primers N6 and the188
PrimeScript™kit (PrimeScript™ One Step RT-PCR Kit Ver.2, TaKaRa) for cDNA synthesis. The cDNA189
was then subjected to qPCR in a 96-well format in triplicate reactions [34] with defined primers190
(Supplementary Table S1) and SYBR® Green (One Step SYBR PrimeScript RT-PCR Kit, TaKaRa). The191
qPCR reactions were performed using StepOnePlus™ Real-Time PCR Systems (Applied Biosystem). The192
expression levels of all genes were normalized to the expression level of the housekeeping gene β-actin and193
then analyzed with the comparative CT(△△CT) method [35].194
195
196
3. Results197
3.1. Clinical characteristics of enrolled subjects198
Table 1: Clinical profiles of the HIV patients and healthy controls used in this study199
Infection situation Age Gender
before ART 2w after ART
IRISViral load
(copies/mL)
CD4
(cells/µl)
Viral load
(copies/mL)
CD4
(cells/µl)
P1 HIV&TB 31 Male 6.08E+07 100 2.89E+02 416 Yes
P2 HIV&TB 45 Male 2.82E+04 213 3.54E+02 235 No
P3 HIV 32 Male 1.08E+05 121 8.76E+03 168 No
H1 Health control 29 Male NA 756 NA 730 No
H2 Health control 27 Male NA 623 NA 660 No
10
ART: Antiretroviral therapy; TB: tuberculosis; NA: not available; IRIS: Immune Reconstitution200
Inflammatory Syndrome;201
202
Three HIV-infected patients (P1, P2 and P3) and two healthy controls (H1 and H2) were enrolled in this study. Table 1203
shows the clinical records pre- and post-HAART. As expected, the CD4-cell counts did not significantly204
change in the two healthy controls (H1 and H2). In all HIV-patients (P1-3), the CD4-cell counts increased205
after HAART, coupled with a dramatic decrease in the HIV load. This finding demonstrated that the206
HAART effectively controlled HIV replication and allowed the host immune system to recover. Compared to207
that of P1 patient, the CD4-cell counts of P2 and P3 patients were mildly increased (less than two-fold) even208
though their virus load reduced by approximately two orders of magnitude (Table 1). P1 had a high virus209
load of 6.08E+07 copies/mL before treatment. After two weeks of HAART, the virus load was reduced to210
2.89E+02 copies/ml. Moreover, P1 showed the best restoration of CD4-cell count among the three patients,211
with more than three-fold increase in CD4-cell count (from 100 cells/µl at pre-treatment to 416 cells/µl at212
post-treatment (Table 1). However, this patient developed TB-IRIS during HAART (data not shown), which is a213
reflection of the high risk for the HIV patients that undergo HAART to develop IRIS214
3.2. Profiling of the PBMC transcriptomes by Overview of the RNA-Seq215
RNA-seq was applied to characterize the transcriptome profile of PBMCs from subjects. Each raw dataset of216
the samples contained between 46 and 60 million reads, with an average of approximately 58 million raw217
reads (5.2 GB of data) per sample. More than 97% bases had a quality score of ≥ Q20. Approximately 218
39~52 × 106 reads (78%-81% of the total raw reads) were aligned to the human genome sequence (Build219
hg19) in each of the samples (Table S1), giving an average of 50 million human reads per sample for further220
analyses.221
222
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The reads that had been uniquely aligned to the transcript sequencing (by RefSeq) were subsequently223
analyzed using the BGI in-house package suites for transcripts abundance normalization and evaluation [28].224
More than 15,000 transcripts were detected in all individuals, while the average of expressed genes was225
17,135. All transcripts of each sample were filtered with a coverage cutoff value of RPKM > 0.7. Using226
RPKM of the qualified the genes, a global expression plot was produced for each individual (Supplementary227
Fig. S1).228
Principal Component Analysis (PCA) was performed on those datasets to compare the similarity and229
variability of gene expression profiles among subjects. Component 1 contribute 48.16% and component 2230
contribute 26.49% of the whole transcriptome. All the samples were detected about 17,000 genes for PCA231
analysis. The PCA results (Fig. 1) indicated that patient P1, who developed a TB-IRIS, had transcriptome232
signature distinct from those of the other patients at both pre- and post-HAART, whereas the transcriptomes233
of P2, P3, H1 and H2 clustered together and displayed similar gene expression profiles (Fig. 1). Given that234
P1 developed TB-IRIS, it is tempting to speculate that the complication of TB-IRIS was accountable for the235
reprogramming of the host’s whole transcriptome Furthermore, the striking alteration in the transcriptome of236
P1 at pre- vs post-treatment (Fig 1) was likely to be a real demonstration of the effectiveness of HAART, in237
light of the dramatic decline of viral load and the considerable recovery of CD4-cells (Table 1). Though238
further investigations are needed to pinpoint the underlying causes of the aberrant transcriptomes in P1, the239
singular transcriptional profiles of P1 were consistent with the unique clinical features of this patient.240
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241
Figure 1. Principal Component Analysis (PCA) of gene expressions in all samples. 0W marked as red242
denotes before HAART, 2W marked as blue denotes two weeks after HAART started. The labelled number243
shows the gene numbers used for each sample.244
245
3.3. Identification of HAART-induced differentially expressed genes (DEGs)246
Even though the total number of genes detected in each subject exceeded 15,000, the numbers of DEGs247
in each individual varied greatly, ranging from >2000 (e.g.P3) to <50 (e.g.H1) (Fig. 2A, Supplementary Fig.248
S1 and Supplementary Table S3 and S4). H1 control had the minimal DEGs in response to HAART (number249
42), while P3 had the most DEGs induced by HAART (number 2,083) (Fig 2A). More DEGs were250
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up-regulated than down-regulated by HAART in P1 and H1, while the opposite was observed for DEGs in251
P2, P3 and H2 (Fig. 2A, Supplementary Fig. S1 and Supplementary Table S3 and S4). These results252
indicated significant inter-individual variations in the DEG profiles in response to HAART (Fig. 2B).253
When all DEGs were compared among these subjects, there was no DEG shared by all subjects,254
including the HIV-patients and controls. 25 DEGs (including 11 downregulated DEGs and 14 upregulated255
DEGs) were shared exclusively by three HIV-patients but not observed in controls (see below for details,256
Supplementary Table S3 and S4, Fig. 3A and Fig 3B). Only one DEG (a downregulated DEG) was shared257
by two controls only but not detected in HIV patients (Fig 3A and Fig 3B). In addition, three DEGs258
(including 1 downregulated DEG and 2 upregulated DEGs) were shared exclusively by HIV-TB patients (P1259
and P2, Fig 3A and Fig 3B). Altogether, there were a total of 29 DEGs which were shared by at least two260
subjects. The lack of overlapping between the HAART-induced DEGs of HIV-patients with those of261
controls was indicative of the specific effects of HAART against HIV infection. The upregulated DEGs and262
downregulated DEGs were described in more detail respectively in the following two sections.263
264
A
14
265
Figure 2. Analysis of differentially expressed genes (DEGs) at pre- and post- HAART. A: The number266
of DEGs for each individual. Red color labels the up-regulation genes and Yellow color labels267
down-regulation genes after HAART. B: DEGs rpkm value heatmap in each individual. Each line represents268
a DEG at least in one sample. Red color labels HAART up-regulated genes and yellow color labels HAART269
down-regulated genes.270
271
3.4. HAART Down-Regulated Genes272
All intersections of the genes down-regulated by HAART among the five individuals are displayed in273
Fig. 3A. The statistical threshold was set at a probability ≥ 0.8 and a fold change of ≥ 2 (NOISeq program 274
[30]). As mentioned above, none of the down-regulated DEGs were shared by all individuals, as indicated275
by the zero DEG in the intersection of all DEG sets (Fig 3A). The intersections of healthy controls (H1 and276
H2)-specific, HIV patients(P1-3)-specific and HIV-TB patients (P1 and P2)-specific DEGs were selected for277
B
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further analyses. The expression changes (measured by RPKM values, Supplementary Table S4) of the278
selected DEGs were illustrated in a heat map for all individuals (Fig. 3B). A single DEG (RNU2-1) was279
shared by the healthy controls (H1 and H2) but not observed in the HIV patients. Apart from this RNU2-1280
gene, the DEG analysis supports that HAART exerts limited side effects on the transcriptome profiles of281
healthy individuals.282
Eleven genes that were down-regulated by HAART were shared by all three HIV-patients(P1-P3) but283
not by normal controls (Fig. 3A). Among them, nine had already been reported for their relevance in HIV284
infections (Supplementary Table S2). The two newly determined genes that were specifically285
down-regulated in HIV-patients were PATL2, which encodes the protein associated with topoisomerase II286
homolog 2 and participates in RNA and protein binding, and RASSF1, which encodes the Ras association287
(RalGDS/AF-6) domain family member 1 and participates in tumor suppression and the induction of cell288
cycle arrest (Supplementary Table S2). A single DEG (CDKN1C encoding the Cyclin-dependent kinase289
inhibitor 1C) was shared by the two HIV-TB patients (Fig. 3A, P1 and P2), whose expression was not290
significantly changed in P3 and H1-2 (Fig. 3B), The alteration in CDKN1C expression might be specifically291
related to TB infection in HIV patients. A heat map cluster analysis (Fig. 3B) separated the two healthy292
controls (H1 and H2) from the three HIV-patients (P1-3) based on these 13 DEGs (including RNU2-1 and293
CDKN1C). Among the HIV-patients, P2 and P3 were clustered together (Fig. 3B) and showed the distinct294
characteristics of the P1 transcriptome, which was also detected in Fig. 1. Two clusters, which were mainly295
the result of the DEG values, formed at the Y-axis of Fig. 3B. We have surveyed the gene in 2 cluster and296
find no significant enrichment in GO term of any cluster. So it may be just the difference in the range of297
down-regulation.298
The down regulation of gene expression after HAART may due to normalization of expression that resulted299
from up-regulation after HIV infection. This can also be confirmed by the compare H1, H2 (control group)300
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vs P1, P2, P3 (patient group) before HARRT. We find 175 DEGs (Table S7) in totally which 129 (73.7%) of301
that was higher in patient group. Furthermore, 54.5% (6/11) of we detected down-regulated genes were302
higher in patient group than control group before HARRT while only 7.1% (1/14) of we detected303
up-regulated genes were lower in patient group.304
305
Figure 3. HAART down-regulated genes. Panel A: Down-regulated DEGs of each individual. Panel B:306
Heat cluster map of HAART down-regulated DEGs in Healthy control (H1 & H2, pink colour word307
labelling), HIV-patient (P1-3, black colour word labelling) and HIV-TB patient (P1 & P2, blue colour word308
labelling). Each DEG value was calculated using RPKM and represented by the formula of309
[log2(RPKM-after/RPKM-before HAART) -1], i.e., zero represents a two folds down-regulation. Star signs310
indicate where the gene expressions were statistically significantly changed.311
312
3.5. HAART Up-Regulated Genes313
As similarly to the down-regulated genes, none of the DEGs up-regulated by HAART were shared314
17
among all five subjects (Fig. 4A), and none were shared by the two healthy controls (H1 and H2). The315
intersections were selected for the HIV patients (P1-3) and HIV-TB patients (P1 and P2). Fourteen of the316
genes up-regulated by HAART were shared by the three HIV patients (P1-3) but not the healthy controls317
(H1 and H2) (Fig. 4A and Supplementary Fig. S1). The relevance of nine of these genes in HIV has already318
been reported (Supplementary Table S3). We identified five novel genes whose expressions were elevated319
by HAART and might be thus suppressed by HIV replication (Fig. 4B, Supplementary Table S3): ACSL1,320
which encodes the acyl-CoA synthetase long-chain family member 1; ADM, which encodes the321
adrenomedullin; GPR84, which encodes the G protein-coupled receptor 84; GPR97, which encodes the G322
protein-coupled receptor 97; and LRG1, which encodes the leucine-rich alpha-2-glycoprotein 1. Based on323
the expression changes of these 14 HAART-up-regulated genes, P2 and P3 were again clustered together324
and differed from P1 (Fig. 4B), as also demonstrated in Fig. 1 and Fig. 3B. Two more genes were identified325
only in the HIV-TB patients: SFXN1, which encodes sideroflexin-1, and SOCS3, which encodes the326
suppressor of cytokine signaling 3 (Fig. 4B, Supplementary Table S3). The relevance of these two genes in327
HIV infection has already been reported in the literature (Supplementary Table S3). Again, the negative328
result in P3 either suggested that the DEG stringency were set excessively high or these genes might be329
affected by the TB co-infection.330
331
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Figure 4. HAART up-regulated genes. Panel A: Up-regulated DEGs for each individual. Panel B: Heat333
cluster map of HAART down-regulated DEGs in Healthy control (H1 & H2, pink colour word labelling),334
HIV-patient (P1-3, black colour word labelling) and HIV-TB patient (P1 & P2, blue colour word labelling).335
Each DEG value was calculated using RPKM and represented by the formula of336
[log2(RPKM-before/RPKM-after HAART) -1], i.e., zero represents a two fold up-regulation. Star signs337
indicate where the gene expressions were statistically significantly changed.338
339
3.6. Validation of the HAART induced DEGs by qRT-PCR340
All of the 29 DEGs shown in Fig. 3 and 4 were experimentally validated using qRT-PCR. The341
qRT-PCR results confirmed our RNA-Seq observations with a 100% precision for the HAART up- and342
down-regulated genes in the HIV patients (Supplementary Table S4). Fig. 5 shows the qRT-PCR results in343
the heat map format. The QRT-PCR result conformed to the RNA-Seq result, which showed that the DEG344
19
profiles of the healthy control (H1 and H2) differed from those of HIV patients (P1-3), as shown in the345
cluster tree at the X-axis in Fig. 5. Among the HIV patients, P2 and P3 were again clustered together,346
illustrating the isolation of P1. At the Y-axis (Fig. 5A-B), the qRT-PCR determined that the up- and347
down-regulated genes formed two main clusters, as detected by RNA-Seq analysis. None of the genes348
changed value was significant difference between qRT-PCR and RNA-seq (wilcoxon rank sum test,349
p>0.05).350
The morphology of the clustering tree also showed similarities, e.g. MX1, CX3CR1, PATL2, CD244351
and RASSF1 were clustered together, while CD160, IFI27 and SIGLEC1 were clustered in both the352
RNA-Seq and qRT-PCR heat maps (Figs. 3 and 5). In the HAART up-regulated gene section (Figs. 3 and 5),353
ADM, CXCL1, S100P, MMP9, GPR84 and LRG1 belonged to a cluster branch, whereas ACSL1, LIMK2 and354
BASP1 clustered in another branch. The DEG clustering relationships may not indicate functional355
connections, but they provide novel information on parallel gene expression changes in response to HAART.356
Most importantly, the consistency of the RNA-Seq and qRT-PCR results indicated that the comparative357
transcriptome approach we used can reliably identify HAART-induced DEGs.358
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Figure 5. Quantitative real time PCR validations of differentially expressed genes. A: the cluster of the361
qPCR value calculated from after/before HAART. Yellow colour labelled heat map squares indicated362
HAART down-regulation and red colour labelling indicated HAART up-regulation. The colour coded363
column next to the cluster tree at Y-axis summarized the RNA-Seq results for HAART down-regulated364
(Brown) and up-regulated (Red) genes specific for the HIV patients (P1-3), HIV-TB patients (P1&2, Blue)365
and healthy controls (H1&2, Purple). B: Boxplot of each gene for the RNA-seq value and qPCR value366
calculated from after/before HAART.367
368
3.7. Gene ontology (GO) analysis of HAART-induced DEGs in HIV patients369
Next we assessed which cellular processes, biological functions or subcellular fractions were influenced by HAART in370
B
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HIV-infected individuals. First we used the perl package of GO-TermFinder-0.86 to draw the GO term371
enrichment figure (Fig. 6) for the whole set of 28 HIV infection relevant genes determined by RNA-seq372
(Figs. 3 and 4) and validated by qRT-PCR (Fig. 5). The 28 HIV-relevant genes were enriched in 39 GO373
terms at three levels (Biological process, cellular component and molecular function, Supplementary Table374
S5). The GO term biological adhesion was down-regulated by HAART (Fig. 6), demonstrating that the375
reduction of viral loads (Table 1) reduced the expressions of adhesion genes. Conversely, the genes in the376
GO terms of pigmentation, growth, reproduction, reproductive process, establishment of localization,377
localization, extracellular region part, extracellular region, transporter activity and antioxidant activity were378
all up-regulated, which shows that HIV activities suppressed the functions of these genes. The gene379
expressions in the other GO terms were not uniformly up-regulated or down-regulated, depending on the380
effect of the gene on the activity in the GO term (positive or negative effect).381
All of the newly determined HIV infection-related genes (i.e. PATL2 and RASSF1 for HAART382
down-regulation; ACSL1, ADM, GPR83, GPR97 and LRG1 for HAART up-regulation; Supplementary383
Tables S2 & S3) were included in the GO terms of cellular process, cell and cell part (Fig. 6). ADM was384
involved in 21 of the 39 detected GO terms, suggesting that its expression might be up-regulated by HAART385
(thus down-regulated by HIV) in multiple pathways. Similarly, RASSF1 and PATL2 were included in 12 and386
11 GO terms, respectively (Fig. 6), suggesting that the observed down-regulations by HAART might be due387
to more than a single functional change. Overall, Fig. 6 clearly shows that HAART which reduced the virus388
load in HIV patients induced many functional changes in PBMC(Table 1). Most importantly, the389
comparative transcriptome approach successfully detected these HIV-affected genes using a very small390
sample size, despite of the tremendous inter-individual variations (Fig. 1 and Supplementary Fig. S1).391
Then we restricted the input for GO analysis to 25 DEGs shared by all HIV patients in an attempt to obtain392
gene function information that is more specific to HIV infection. Generally, GO analysis revealed that393
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HAART regulated the expression of genes enriched in seven GO terms: soluble fraction, magnesium ion394
binding, immune response, behavior, defense response, cellular defense response, and response to virus.395
With respect to the HAART down-regulated DEGs in HIV patients, they fell into four GO terms, including396
soluble fraction, magnesium ion binding, immune response and behavior (Fig. 6, Supplementary Table S6).397
With regard to the HAART upregulated DEGs in HIV patients, they were enriched in the GO terms of398
immune response, behavior, defense response, cellular defense response, and response to virus (Fig 6,399
Supplementary Table S6). It is notable that genes involved in three cellular processes including defense400
response, cellular defense response, and response to virus were all upregulated by HAART in HIV patients401
(Fig 6, Supplementary Table S6), suggesting that without HAART, HIV would otherwise suppress the402
processes of cell defense and stress resistance in patients. In addition, immune response was revealed to be403
regulated by HAART in patients (Fig 6), which was quite expected. Taken together, these identified GO404
terms are consistent with the current knowledge on HIV-host interaction, which confirms that even on a405
small number of subjects, the RNA-seq based comparative transcriptome approach proves a powerful and406
sensitive tool to yield true biological insights.407
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408
Figure 6. The enriched GO term of selected 28 differentially expressed genes. Red bars indicate the409
up-regulated genes, while yellow bars indicate the down-regulated genes. The X-axis indicates the enriched410
GO term, classified into 3 levels: biological process, cellular component and molecular function. The Y-axis411
shows the percentage of up- or down-regulated DEGs in certain GO term, the number above bars indicate412
the amount of 28 DEGs enriched into certain GO term with the names of the newly determined genes413
associated with HIV infection.414
415
Gene Set Enrichment Analysis (GSEA)416
To get a more comprehensive and biologically meaningful overview of HAART-regulated cellular processes,417
we conducted GSEA on the RNA seq data. Different to the DEG analysis, GSEA analysis the performance418
of a gene set (pathway) between the two samples. It also calculated the statistics using all biological419
replicates in a treatment, i.e., HIV patients and HIV negative volunteers in this study. Among the 50420
pre-defined gene sets provided by the MSigDB, 14 pathways were upregulated specifically to the HIV421
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patients by HAART (Fig. 7). Seven pathways were upregulated in both HIV patients and the HIV negative422
volunteers in whom two more pathways were also upregulated by HAART (Fig. 7). In comparison, five423
HAART upregulated DEGs (ADM, AQP9, BASP1, IL1R2 and MMP9, Fig. 4) were specific for the HIV424
patients (not being members of the gene sets identified for the HIV negative volunteers) (Supplementary425
Fig.S2). Among them, ADM was a new HIV related gene identified in this study (Fig.6). It encodes426
adrenomedullin, a peptide hormone which is involved in inflammatory response and hypoxia (Supplementary427
Fig.S2). The inflammatory response pathway also involves AQP9 (aquaporin 9) which has been reported for428
involvements of HIV-associated dementia [36]. The hypoxia gene set also contains MMP9 encodes the429
matrix metallopeptidase 9 which activities are associated with cardiovascular diseases in HIV patients [37].430
431
Figure 7. GSEA gene sets significantly affected by HAART. Venn chat shows HAART upregulated432
pathways uniquely detected in HIV patients (left) and HIV negative volunteers (right) or shared by both433
(middle).434
435
436
4. Discussion437
438
Metabolic abnormalities and systemic immune dysfunctions are common during HIV infection and/or439
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antiretroviral therapy. Although some transcriptomic studies of HIV infection have revealed global changes440
in the mRNA and microRNA expression profiles [11, 34, 38, 39], the molecular mechanisms that contribute441
to these dysfunctions have remained elusive, and the relationship between the PBMC transcriptomic profiles442
and the differential responses to antiretroviral therapy has been limited for HIV patients. Using443
transcriptomic analysis based on RNA-Seq, we identified a number of transcriptional features and specific444
genes that may contribute to the HIV associated dysfunction in vivo and provided further insights into the445
molecular mechanisms of antiretroviral therapy effects on HIV patients.446
The differentially expressed genes (DEGs) significantly differed among the five individual subjects (Fig.447
2A). H1, who was a healthy volunteer, only expressed 13 HAART down-regulated and 28 up-regulated448
genes, showing that HAART may only minimally affect the PBMC gene expressions in a healthy person.449
Despite of the inter-individual variations, 25 DEGs shared by the three HIV patients were identified,450
demonstrating the power of the comparative transcriptome analyses. Among the 11 HAART-down-regulated451
genes, the relevance of nine had already been reported in HIV infection (CD160, CD244, SIGLEC1, IFIT1,452
IFI44, IFI27, CX3CR1, IFI44L and MX1). These genes could directly interact with HIV, take part in453
immune activation and participate in host defenses that partially control infection (Supplementary Tables S2454
& S3). For example, CD160 and CD244 are negative surface receptors expressed on NK cells and activated455
T cells [21, 40]. The co-expression of multiple distinct inhibitory receptors is associated with greater T cell456
exhaustion and rapid HIV disease progression [40]. HIV exploits the effects of the molecular immune457
inhibitory response to facilitate the virus’s escape under the surveillance of the immune system [41]. Several458
studies found that the suppression of HIV replication by antiretroviral therapy could reduce the surface459
expression of inhibitory molecules on HIV-specific immune cells [4-7], which was also supported by our460
results.461
Four of our detected HAART down-regulated genes (IFIT1, IFI44, IFI27 and Mx1) belong to the462
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interferon (IFN) inducible gene family and are related to immune activation and immune defenses. After463
HIV infection, interferon signaling leads to the induction of IFN-stimulated gene (ISGs) expression, which464
results in the diverse effects of IFNs, including anti-viral replication, immune modulation and antitumor465
activity. Previous array studies documented that both HIV-1 infection and viral proteins increased the466
expression of IFN-inducible genes, and ART efficiently mitigated aberrant gene expression [14, 42-44].467
Most prominently, MxA(Mx1), a known interferon-induced restriction factor for a diverse range of viruses,468
may represent a valuable marker to monitor the clinical response to therapy in HIV patients because the469
levels of serum interferon-alpha and MxA mRNA were significantly higher in HIV-infected patients with470
low CD4 T-cell counts, and the expression of MxA directly correlated with HIV RNA copy numbers [45].471
Clinical trials also showed that the CD4 T-cell count increased and the HIV-induced cytokine IFN-alpha and472
its downstream effector MxA decreased in the plasma of HIV patients after seven years of antiviral treatment473
[46].474
CX3CR1 is a co-receptor for HIV-1, and some variations increases the susceptibility to HIV-1 infection475
and rapid progression to AIDS [47]. SIGLEC1 (CD169), which is expressed on IFN-induced monocytes,476
binds HIV-1 and enhances infectivity [48]. These two factors, which are up-regulated after HIV-1 infection477
and increase during disease progression [49], directly interact with HIV and may be potential molecular478
targets associated with the inhibition of virus spread [50]. Li et al. [51] proposed a disease model in which479
the host rapidly responds to HIV-1 infection by increasing the expression of a large number of genes related480
to the innate and adaptive defenses after HIV infection. The suppression of viral replication by HAART481
would relieve the stimulus from HIV，thus leading to the decreased expression of these genes [52]. Our482
results support these previous reports, which demonstrate that the comparative transcriptome approach can483
efficiently extract valuable information from a large number of detected genes using a small sample set, i.e.484
samples from three HIV-patients and two HIV negative volunteers.485
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Two genes (PATL2 and RASSF1), whose relationship to HIV infection had not previously been reported,486
were identified in this study. Although PATL2 and RASSF1 have been implicated in cell division and tumor487
suppression, respectively [53-55], their patterns of down-regulation were similar in the three HIV patients488
during HAART, as judged by RNA-Seq (Fig. 3B) and qRT-PCR (Fig. 5). This finding suggested that the489
production of PATL2 and RASSF1 increased during the HIV infection before treatment. Because all three490
HIV patients shared these two DEGs despite the tremendous inter-individual variations (Figs. 1, 2, and 3A;491
Supplementary Fig.S1), HIV infection likely resulted in the over-expressions of PATL2 and RASSF1.492
Therefore, further investigations to determine the relationships of these two proteins with HIV pathogenesis493
will be worthwhile for treatment development.494
Fourteen genes (ACSL1, GPR84, CXCL1, ADM, S100P, AQP9, GPR97, BASP1, MMP9, SOD2, LRG1,495
LIMK2, IL1R2 and BCL2A1) were up-regulated by HAART in HIV patients compared with the healthy496
controls. It is worth to note that HAART up-regulation indicated HIV down-regulation but was not497
correlated to CD4+ cell enrichment in these samples. Based on the commonly accepted notion that there is498
no “signature genes” in CD4+ cells [56], up-regulations of the genes mentioned above should not be due to499
the increase of CD4+ cells. Indeed, the CD4+ cell counts did not increase (less than half-fold in P2 and P3,500
Table 1) proportionally to the RKPM changes (Supplementary Table S4) indicating that the DEGs we501
recorded (with more than two-fold RKPM change) were not largely due to the increase of CD4+ cell counts502
although contributions of the CD4+ cells could not be ruled out completely. Therefore, it was mainly the503
HIV infection that suppressed the expressions of these genes. The relationships of the majority of these504
genes (9 out 14) with HIV infection had already been reported (Supplementary Table S3). Interestingly,505
some of the five new genes (ACSL1, ADM, GPR84, GPR97 and LRG1) play key roles in fatty acid506
metabolism, cell cycle arrest and immunological dysfunction (Fig. 6). For example, GPR97 is an orphan507
adhesion protein-coupled receptor that binds to chemokines on the surfaces of immune cells. GPR97 has508
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been suggested to regulate the migration of lymphatic endothelial cells [57] and B-cell development [58],509
but it has not yet been specifically associated with the host immune responses to a virus. The up-regulation510
of GPR97 by HAART suggests that HIV may interfere with some G-protein coupled receptors that are511
relevant to chemokine signaling pathways, which may be critical for effective antiviral immune responses.512
Cardiovascular disease (CVD) has emerged as one of most critical complications of HIV infection.513
Several clinical studies demonstrated that the rates of CVD among HIV-infected patients were514
approximately 1.5–2-fold higher than uninfected controls [59-62]. However, the cause of HIV contributing515
to an increased risk of CVD is still unclear. It has been suggested that HIV-associated CVD may link to516
T-cell activation, chronic infection, monocyte and macrophage related inflammation and dysfunctional517
immune regulatory responses [63-69]. We found the up-regulation of ADM expression in HIV patients was518
associated with the decease of HIV load after HAART although ADM had not been reported for association519
with HIV infection before. ADM has physiological and pathophysiological functions in the cardiovascular520
system including vasodilation, natriuresis, stimulation of NO production and inhibition of apoptosis [70-72].521
ADM also plays a protective role in various pathological conditions including hypertension, myocardial522
infarction, renal failure and heart failure [73, 74]. As we showed that HAART elevated the level of ADM523
expression in HIV patients but not in HIV negative volunteers, it strongly suggested that HIV infection524
suppressed the expression of ADM in PBMC. Although direct evidence is needed to clarify the relationship525
between HIV activity and ADM levels, it is tempting to consider the therapeutic possibility that ADM may526
be used to treat HIV-associated diseases as ADM is involved in many biological functions (Figs. 6 & 8).527
Finally, our work showed that HAART resulted in significant inter-individual variability among DEGs,528
which reflected the diversity in HIV-affected human gene expressions (Figs. 1-4). These observations also529
highlighted the importance of determining common as well as personal specific DEG profiles to develop530
effective diagnostic markers and treatment targets.531
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5. Conclusions532
In this study, we use RNA sequencing (RNA-Seq) technology to identify common DEGs and special533
DEGs for HIV positive and HIV negative person between pre- and post- HAART. We found 11534
down-regulate DEGs and 14 up-regulated DEGs in HIV positive patient. Our work showed that HAART535
resulted in significant inter-individual variability among DEGs, which reflected the diversity in536
HIV-affected human gene expressions. The newly identified HIV-related genes, ADM (which encodes537
Adrenomedullin), a peptide hormone in circulation control, may contribute to HIV-associated hypertensions,538
providing new insights into HIV pathology and novel strategies for developing anti-HIV target. These539
observations also highlighted the importance of determining common as well as personal specific DEG540
profiles to develop effective diagnostic markers and treatment targets.541
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Supplementary Table S1. The summary of sequencing datasets
Sample ID
Total Reads
(M)
Total Base
Pairs (G)
Total
Mapped (%)*
Perfect
Match (%)**
Unique
Match (%)***
P1-0W **** 59.61 5.36 80.40 64.75 73.53
P1-2W 59.64 5.37 80.35 64.30 76.28
P2-0W 59.52 5.36 75.68 60.14 73.71
P2-2W 59.75 5.38 73.66 58.56 71.69
P3-0W 59.73 5.38 77.69 62.24 75.41
P3-2W 59.13 5.32 75.11 60.13 72.50
H1-0W 46.26 4.16 81.92 65.47 79.50
H1-2W 59.32 5.34 80.73 64.69 78.61
H2-0W 58.88 5.30 75.33 60.84 68.16
H2-2W 58.74 5.29 75.47 60.20 68.39
* Reads were mapped against human reference sequence
** Reads perfectly matched to the human reference sequence
*** Reads uniquely matched to a single location in the human reference sequence
**** 0W denotes pre-HAART and 2W denotes 2 weeks after HAART started
Name Sequence Name
Forward primer: AGGATTTGAAGGGTCGTTTG
Reverse primer: TAATTCAGGGTGCAATGTGAT
Forward primer: TACACCGCCAGGTCAAACG
Reverse primer: ACTGGGTCCTCCTGATGCTAA
Forward primer: CGAGTGTTTGCCAGGCTTAA
Reverse primer: GCGTGAGAAATCAGTTTGTGG
Forward primer: ACACGCAGACCCTGACCAA
Reverse primer: CAGCCACGAACACGATGAAC
Forward primer: TCCAGTTCCCGCTATGCT
Reverse primer: GAATGCCACAATGTCCTCC
Forward primer: CAGAGATACTGGCTAAACTACG
Reverse primer: TCTCTTGGGAAGTCGCAC
Forward primer:TAGCACCCAGAGCCGAACT
Reverse primer: AGGCTTTCTCGTCGTTCACA
Forward primer: CAGGCGCTCATGTACCCTA
Reverse primer: TCAGGGCGAGGACCATAGA
Forward primer: TGGAGCACGCTTACTACCTTC
Reverse primer:GCAAGCCATGTATCTTTCAGTT
Forward primer: TTCAACCTGACCCACCTGC
Reverse primer: AGGGCGTTTCGGGTTAGAT
Forward primer: GGCTGAGAACTTACGGACAACA
Reverse primer: GAGCCCACCCGAGTATGAGTA
Forward primer: AGATGCTTTCCTGCCGTT
Reverse primer: TCACTCAGGTCAGGGCATAC
Forward primer: TGCGTCCTACAGATACCACAA
Reverse primer: GTGTTCTGGCAGTGTCTACGG
Forward primer:TCAGAAGGGAGGAGGAAGC
Reverse primer: CTCCTAAGCGATGCTCAAACA
Table S1: All primer sequences for qRT-PCR verification
IFI27
Mx1
CX3CR1
SIGLEC1
PATL2
RASSF1
BCL2A1
CXCL1
RNU2-1
SFXN1
SOCS3
CDKN1C
CD160
CD244
IFIT1
IFI44
IFI44L
BASP1
GPR97
MMP9
SOD2
LRG1
LIMK2
IL1R2
ACSL1
GPR84
ADM
S100P
AQP9
Sequence
Forward primer: CACAGTGACGGGATTGAAACA
Reverse primer: GGTGACCAGCATTACCCAGAC
Forward primer: CACCTAAAGCCCAGAACCCT
Reverse primer: AACTCCTGTGCCGTCATCC
Forward primer: GCTCAAATCCCTTCCGCTAT
Reverse primer: TTCCAGGCGATAGGCAGAG
Forward primer: TCCCTGGTTCAACAAATACGA
Reverse primer: TATGCCCACCAAAGCCTGA
Forward primer: ACAGAGCCAAATGATTCCCTATG
Reverse primer: TCGATAAACGACACACCAGTTG
Forward primer: TGCTCTCACCTCATCAGCAGT
Reverse primer: CACAACTCCTCCAATCACAACT
Forward primer: GGTGGTCCCCAGTAATGTGG
Reverse primer: CGTCAAGATTCCGATGGTCCT
Forward primer: GCTCTTCTGGACACCCTACAAC
Reverse primer:CTCAGGCAACAATGGCTAAAT
Forward primer: CCACTAGGGCTGATACTGGCT
Reverse primer: GAGGCGGGTGGTTGACTAC
Forward primer: GAGGCTTATGAGTCCGTGGTC
Reverse primer: ACTTCCAGCCTTCCTCTATTTC
Forward primer: TAGGGTGGGTGCTCAGAATAA
Reverse primer: AACCAGCACTCCCTGACCT
Forward primer: GCCTTTTGGCTAAGATCAAGT
Reverse primer: TACTGCAATACCAGGTCGATG
Forward primer:AAGTTGGCATTCCCGTCAC
Reverse primer: GAGAATCCTGGACACGACAAC
Forward primer: GAGTTCCTGGACCAGTACGATG
Reverse primer: TCTGGTTGGCTTCTTGTGCT
Forward primer: CCAAAGGCACTCTCCATCTC
Reverse primer: GCTAGATGGGCATGTATGGC
Table.S3: Eleven down-regulated DEGs in HIV infected patients, one down-regulated DEGs in HIV/TB co-infected patients and
one down-regulated DEGs in healthy controls by antiretroviral therapy.
Gene ID
Gene
symbol full_name function descripton
RefSeq
Accession HIV relevant studies Reference
11126 CD160 CD160 molecule negative regulator of T cell activation NM_007053 CD160 was up-regulated on HIV-specific CD8 T lymphocytes mostly
during the chronic phase of infection.
[1-4]
51744 CD244 natural killer cell receptor 2B4 modulate NK-cell cytolytic activity and inhibitory receptor in
CD8+ T cells
NM_016382 2B4 expression on natural killer cells increases in HIV-1 infected
patients
[5-7]
3434 IFIT1 Interferon-Induced Protein With
Tetratricopeptide Repeats 1
inhibit viral replication and translational initiation NM_001548 HIV infection induces the expression of IFIT1. [8-11]
10561 IFI44 interferon-induced protein 44 Antiproliferative activity and inhibit viral replication NM_006417 HIV-1 infection or Tat expression induces interferon (IFN)-responsive
gene expression（IFI44,IFI27，MX1)
[8, 9,
12-14]
10964 IFI44L interferon-induced protein
44-like
immune defense response to virus NM_006820 HIV-1 gp120-treated vaginal epithelial cells show upregulation of
IFI44Lexpression
[15]
3429 IFI27 interferon, alpha-inducible
protein 27
inhibit viral replication and enhances the immune response NM_005532 HIV downregulates interferon-stimulated genes in primary
macrophages; IFI27 expression in HIV/HCV co-infection.
[12, 16, 17]
4599 Mx1 myxovirus (influenza virus)
resistance 1
participates in the cellular antiviral response NM_002462 Regulation of interferon-alpha-inducible cellular genes in human
immunodeficiency virus-infected monocytes
[18-22]
1524 CX3CR1 chemokine (C-X3-C motif)
receptor 1
the adhesion and migration of leukocytes NM_001337 coreceptor for HIV-1 and increased susceptibility to HIV-1 infection
and rapid progression to AIDS
[23]
6614 SIGLEC1 sialic acid binding Ig-like lectin 1 mediating cell-cell interactions，Binds HIV-1 and Enhances
Infectivity
NM_023068 virus-cell interactions between HIV-1 and Siglec1/CD169, a protein
expressed on dendritic cells
[24, 25]
197135 PATL2 protein associated with
topoisomerase II homolog 2
RNA binding and protein binding NM_001145112 No report
11186 RASSF1 Ras association (RalGDS/AF-6)
domain family member 1
the tumor suppressor function and induce cell cycle arrest NM_170712 No report
1028 CDKN1C Cyclin-dependent kinase
inhibitor 1C
strong inhibitor of several G1 cyclin/Cdk complexes and a
negative regulator of cell proliferation
NM_000076 HIV-1-infected cells lose their G(1)/S checkpoints due to a loss of
cycline-dependent kinase inhibitor.
[26]
6066 RNU2-1 RNA, U2 small nuclear 1 a RNA component of the U2 snRNP that interacts with the 3'
region of the intron at the branch site
N/A No report
Table.S4: Fourteen up-regulated DEGs in HIV-infected patients and two up-regulated DEGs in HIV/TB co-infected patients by
antiretroviral therapy
Gene
ID
Gene
symbol Full name function descripton
RefSeq
Accession HIV relevant studies Reference
2180 ACSL1 acyl-CoA synthetase long-chain
family member 1
Activation of long-chain fatty acids for both synthesis of
cellular lipids, and degradation via beta-oxidation
NM_001995 No report
53831 GPR84 G protein-coupled receptor 84 fatty acid metabolism and immunological regulation NM_020370 No report
133 ADM adrenomedullin a hormone in circulation control NM_001124 No report
6286 S100P S100 calcium binding protein P the regulation of a number of cellular processes such as cell
cycle progression and differentiation
NM_005980 Potential therapeutic targets for HIV infection [10]
366 AQP9 aquaporin 9 water-selective membrane channels，immunological
response and bactericidal activity
NM_020980 Brain water channel proteins involved in HIV-associated dementia and
transcription profile of CD4(+) T cells in HIV/HCV co-infection.
[27, 28]
222487 GPR97 G protein-coupled receptor 97 regulating migration of lymphatic endothelial cells and B-cell
development
NM_170776 No report
10409 BASP1 brain abundant, membrane
attached signal protein 1
transient phosphorylation sites and PEST motifs NM_006317 HIV-1 Tat up-regulates the expression of BASP1 in human primary T
cells
[29]
4318 MMP9 matrix metallopeptidase 9 breakdown of extracellular matrix，embryonic development,
reproduction, and tissue remodeling
NM_004994 MMP-9 activity levels are associated with cardiovascular diseases [30]
6648 SOD2 superoxide dismutase 2 converts superoxide byproducts of oxidative phosphorylation
to hydrogen peroxide and diatomic oxygen.
NM_000636 HIV gp120 regulate SOD2 in HIV-associated dementia. [31]
116844 LRG1 leucine-rich alpha-2-glycoprotein
1
Protein-protein interaction, signal transduction, and cell
adhesion and development.
NM_052972 No report
3985 LIMK2 LIM domain kinase 2 a TKL kinase of the LISK family that regulates actin dynamics NM_005569 the RhoA-ROCK-LIMK-cofilin pathway in HIV-1 infection [32, 33]
7850 IL1R2 interleukin 1 receptor, type II MAPK signaling pathway and IL1-mediated signaling events NM_004633 Gene expression profiling of the host response to HIV-1 infection in
monocyte-derived dendritic cells
[34]
597 BCL2A1 BCL2-related protein A1(Bfl-1) anti- and pro-apoptotic regulators NM_004049 Gp120-induced M-CSF up-regulates the anti-apoptotic genes Bfl-1 [35]
2919 CXCL1 Chemokine (C-X-C motif) ligand
1
Playing a role in inflammation as a chemo-attractant for
neutrophils.
NM_001511 Induction of IL-17 and T-cell activation by HIV-Tat protein [29]
94081 SFXN1 Sideroflexin-1 double-stranded RNA-binding protein NM_022754 Combine with HIV RNA and form RNP in host cells, participate in the
formation of HIV packaging.
[36]
9021 SOCS3 Suppressor of cytokine signaling
3
cytokine-inducible negative regulators of cytokine signaling NM_003955 HIV-1 Tat upregulates SOCS3 in human primary T cells; HIV-1 gp120
recruits SOCS3 through IL-10 activation.
[29, 37]
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RNA-Seq 4.9045 2.713 4.9778 1.0105 1.6471 RNA-Seq
qRT-PCR 1.6054 2.3649 3.3525 0.0588 2.0155 qRT-PCR
RNA-Seq 19.1131 19.4881 9.8669 0.6384 2.429 RNA-Seq
qRT-PCR 17.9598 1.3735 6.0613 0.7166 3.1033 qRT-PCR
RNA-Seq 3.002 2.5947 4.7298 1.2455 0.6661 RNA-Seq
qRT-PCR 1.663 2.4123 4.2212 0.6572 0.983 qRT-PCR
RNA-Seq 12.5075 5.9117 4.5421 1.1487 0.504 RNA-Seq
qRT-PCR 2.2944 7.638 33.8234 0.1231 1.1661 qRT-PCR
RNA-Seq 4.9533 2.0229 2.9232 1.1339 1.0012 RNA-Seq
qRT-PCR 3.7711 3.0229 3.5393 0.0423 2.237 qRT-PCR
RNA-Seq 16.8083 5.2271 10.2704 0.8588 0.2645 RNA-Seq
qRT-PCR 2.3841 3.0773 3.9276 0.0933 0.0172 qRT-PCR
RNA-Seq 2.2714 2.1709 2.9246 1.7223 0.8152 RNA-Seq
qRT-PCR 1.615 6.2051 3.3212 0.902 0.8447 qRT-PCR
RNA-Seq 2.3251 7.7073 10.2766 2.8546 0.4773 RNA-Seq
qRT-PCR 1.5463 6.077 7.3214 1.0614 1.7898 qRT-PCR
RNA-Seq
qRT-PCR
SOD2
the ratio of the RNA quantitative values after to before ARTGene
symbol
ACSL1
GPR84
ADM
Method Genesymbol
CD160
CD244
S100P
AQP9
GPR97
BASP1
MMP9
LIMK2
IL1R2
BCL2A1
CXCL1
Table S5. Quantitative real time PCR validations of differentially expressed genes
NOTE: The numbers are the ratios of gene expression levels (obtained by RKPM for RNA-Seq and qRT-PCR) of after/before HAART.
Red colour filled boxes show statistically significantly HAART up-regulated genes and yellow colour filled boxes are
significantly HAART down-regulated genes. Unfilled boxes indicate data without a statistical significance (P>0.001). Red
colour words show the names the HAART up-regulated genes in HIV patient; Yellow colour words show the HAART down-regulated
genes in HIV patient; Blue words show the DEGs shared by the HIV-TB patients (P1 and P2); Pink words show the DEG determined
in the healthy controls (H1 & H2).
CDKN1C
Method
SIGLEC1
PATL2
RASSF1
RNU2-1
SFXN1
SOCS3
IFIT1
IFI44
IFI44L
IFI27
Mx1
CX3CR1
LRG1
P1 P2 P3 H1 H2
0.3555 0.2572 0.1424 0.8154 0.6999
0.3301 0.1442 0.1141 0.0624 1.904
0.4647 0.3925 0.4051 0.869 0.6537
0.2836 0.3563 0.3663 0.2394 2.078
0.4261 0.1271 0.2563 0.8252 0.746
0.3609 0.3219 0.2384 0.4323 2.7942
0.3885 0.4709 0.3065 0.7473 0.7289
0.2839 0.0186 0.0217 0.111 2.0096
0.2591 0.1058 0.0878 0.6188 0.4146
0.2983 0.2966 0.1981 0.4313 0.992
0.1064 0.1005 0.0777 0.205 0.2854*
0.1655 0.0417 0.0573 0.0149 0.8586
0.4985 0.398 0.2485 0.9474 0.7496
0.3741 0.7309 0.2137 0.4185 1.2033
0.3974 0.4351 0.1999 0.9036 0.5644
0.1353 0.5893 0.5787 0.2619 0.242
0.0531 0.0181 0.0359 1.3492 0.4373
0.0298 0.2325 0.032 0.7072 2.1963
0.4721 0.2537 0.3161 0.8557 0.5803
0.5176 0.8149 0.3946 0.128 1.5548
0.4727 0.4765 0.4918 0.6594 1.2838
0.0909 0.8922 0.3156 0.0174 1.3913
0.523 2.487 1.0465 0.1002 0.4571
0.5162 4.421 1.9501 0.0821 0.2086
2.0863 2.1977 1.4087 1.1267 1.6689
1.7206 6.0214 4.1821 0.2179 2.8734
2.4823 2.4005 1.8402 1.1382 0.7431
1.9737 2.9656 2.8918 0.4732 2.0134
0.1088 0.1365 0.2654* 0.8082 0.6689
0.1058 0.2964 0.6368 0.063 0.0035
the ratio of the RNA quantitative values after to before ART
Table S5. Quantitative real time PCR validations of differentially expressed genes
NOTE: The numbers are the ratios of gene expression levels (obtained byRKPM for RNA-Seq and qRT-PCR) of after/before HAART.
Red colour filled boxes show statistically significantly HAART up-regulated genes and yellow colour filled boxes are
significantly HAART down-regulated genes. Unfilled boxes indicate data without a statistical significance (P>0.001). Red
colour words show the names the HAART up-regulated genes in HIV patient;Yellow colour words show the HAART down-regulated
genes in HIV patient; Blue words show the DEGs shared by the HIV-TB patients (P1 and P2); Pink words show the DEG determined
GO Class No. up-regulated genes
biological_processbiological adhesion 0
biological_processbiological regulation13
biological_processcell proliferation 3
biological_processcellular component organization or biogenesis4
biological_processcellular process 14
biological_processdeath 5
biological_processdev lopmental process6
biological_processestablishment of localization2
biological_processgrowth 1
biological_processimmune system process6
biological_processlocalization 4
biological_processlocomotion 3
biological_processmetabolic process 6
biological_processmulti-organism process2
biological_processmulticellular organismal process9
biological_processnegative regulation of biological process5
biological_processpigmentation 1
biological_processp sitive regulation of biological process4
biological_processregulation of biological process11
biological_processreproduction 2
biological_processreproductive process2
biological_processresponse to stimulus10
biological_processsignaling 6
cellular_componentcell 12
cellular_componentcell part 12
cellular_componentextracellular region 3
cellular_componentextracellular region part3
cellular_componentacromolecular complex1
cellular_componentembrane-enclosed lumen1
cellular_componentorganelle 6
cellular_componentorganelle part 4
molecular_functionantioxidant activity 1
molecular_functionbi ding 9
molecular_functioncatalytic activity 4
molecular_functionenzyme regulator activity2
molecular_functionmolecular transducer activity1
molecular_functionreceptor activity 1
molecular_functiontransporter activity 1
Up-regulated genes
-
AQP9;ADM;SOD2;GPR97;LIMK2;SOCS3;MMP9;S100P;SFXN1;CXCL1;BCL2A1;ACSL1;GPR84
ADM;CXCL1;SOD2
SOD2;MMP9;ADM;CXCL1
ADM;SOD2;GPR97;LIMK2;SOCS3;MMP9;S100P;AQP9;CXCL1;SFXN1;BCL2A1;ACSL1;GPR84;LRG1
SOD2;BCL2A1;SOCS3;MMP9;ADM
SOD2;ADM;SOCS3;MMP9;SFXN1;LRG1
SFXN1;AQP9
SOCS3
MMP9;SFXN1;SOD2;AQP9;CXCL1;IL1R2
SFXN1;MMP9;AQP9;S100P
MMP9;CXCL1;S100P
ADM;SOD2;LIMK2;SOCS3;ACSL1;MMP9
ADM;SOCS3
ADM;LIMK2;AQP9;S100P;MMP9;SOD2;SFXN1;SOCS3;ACSL1
ADM;CXCL1;SOD2;BCL2A1;SOCS3
SOD2
ADM;SOD2;MMP9;SOCS3
ADM;GPR97;SOD2;LIMK2;SOCS3;MMP9;S100P;CXCL1;BCL2A1;ACSL1;GPR84
LIMK2;ADM
LIMK2;ADM
AQP9;ADM;SOD2;GPR97;SOCS3;CXCL1;ACSL1;GPR84;S100P;IL1R2
GPR97;S100P;SOCS3;GPR84;ADM;CXCL1
BASP1;ACSL1;SFXN1;SOD2;LIMK2;AQP9;LRG1;GPR84;GPR97;ADM;S100P;IL1R2
BASP1;ACSL1;SFXN1;SOD2;LIMK2;AQP9;LRG1;GPR84;GPR97;ADM;S100P;IL1R2
ADM;CXCL1;MMP9
ADM;CXCL1;MMP9
AQP9
SOD2
BASP1;ACSL1;SFXN1;SOD2;LIMK2;LRG1
ACSL1;SFXN1;SOD2;LIMK2
SOD2
MMP9;SOD2;LIMK2;ACSL1;SFXN1;CXCL1;S100P;IL1R2;ADM
SOD2;MMP9;LIMK2;ACSL1
CXCL1;SOCS3
IL1R2
IL1R2
AQP9
No. down-regulated genesDown-regulated genes
2 SIGLEC1;CX3CR1
6 CDKN1C;RASSF1;MX1;PATL2;CD160;CX3CR1
1 CDKN1C
1 PATL2
7 CDKN1C;RASSF1;MX1;SIGLEC1;PATL2;CD160;CX3CR1
1 MX1
1 CDKN1C
0 -
0 -
1 IFI44L
0 -
1 CX3CR1
2 CDKN1C;PATL2
2 IFI44;MX1
1 CDKN1C
3 CDKN1C;RASSF1;PATL2
0 -
2 MX1;CDKN1C
6 CDKN1C;RASSF1;MX1;PATL2;CD160;CX3CR1
0 -
0 -
8 CDKN1C;RASSF1;CX3CR1;SIGLEC1;IFI44;MX1;CD160;IFI44L
4 CDKN1C;RASSF1;CD160;CX3CR1
9 PATL2;RASSF1;CD160;CD244;CX3CR1;SIGLEC1;CDKN1C;IFI27;MX1
9 PATL2;RASSF1;CD160;CD244;CX3CR1;SIGLEC1;CDKN1C;IFI27;MX1
0 -
0 -
2 PATL2;RASSF1
1 CDKN1C
3 RASSF1;CDKN1C;PATL2
2 CDKN1C;RASSF1
0 -
5 CX3CR1;MX1;PATL2;RASSF1;SIGLEC1
1 MX1
1 CDKN1C
2 CX3CR1;CD160
2 CX3CR1;CD160
0 -
gene_name gene_id log2Ratio(P1-3W0/H1-2W0) probability
GBP2 2634 1.16538582 0.810102174
REC8 9985 1.78562432 0.803503456
SERPING1 710 4.03737325 0.913527998
RSAD2 91543 3.957803761 0.911812581
CD8B 926 1.492125445 0.847941501
CD38 952 1.763209738 0.836697386
ISG15 9636 2.964163193 0.914629871
DUSP2 1844 1.20185218 0.818879595
TRIM22 10346 1.352712235 0.833542021
DEFA4 1669 4.548287623 0.915969648
EGR2 1959 2.076514159 0.869465592
UBE2L6 9246 1.171467765 0.809601322
USP18 11274 3.617106812 0.889624862
CXCR2P1 3580 1.641330363 0.823086747
STAT1 6772 2.018311458 0.883101272
IGJ 3512 1.772408374 0.874273765
BPGM 669 1.537705167 0.827631974
SAMD9L 219285 1.480216584 0.818754382
OAS1 4938 1.510729019 0.841543123
CCL2 6347 2.470056103 0.87051738
HELZ2 85441 1.561662116 0.802326455
HERC5 51191 2.251125148 0.852837323
IFIT1B 439996 5.344627464 0.833892617
DEFA3 1668 4.885945931 0.954973455
AHSP 51327 5.234315115 0.9522939
RAP1GAP 5909 7.094227082 0.832590404
HLA-DRB4 3126 9.629255004 0.984673946
RGS1 5996 1.262964965 0.806683863
SIGLEC1 6614 4.76034878 0.927401583
GBP5 115362 2.032806139 0.881661324
CD8A 925 1.787166248 0.871331263
HBD 3045 5.634450818 0.968534008
IFI44 10561 2.997462039 0.908306621
CLC 1178 1.693672242 0.845938095
ELANE 1991 3.741351203 0.848955725
IRF7 3665 1.703887217 0.857006912
EPSTI1 94240 2.725875583 0.90274717
HBG2 3048 1.974864012 0.866660823
IGLL5 100423062 1.187871736 0.818791946
SELENBP1 8991 4.761776345 0.924734549
MIR5047 100616408 1.98938992 0.804430031
MYL4 4635 2.724007171 0.801387359
LAG3 3902 1.720486167 0.828508464
OAS2 4939 1.937650696 0.874248723
CTSG 1511 3.954614514 0.813295102
DDX60 55601 1.917395194 0.830937594
CA1 759 4.213682382 0.922630973
GBP1 2633 2.962299857 0.903298107
EGR1 1958 1.256771365 0.82486477
LENG8 114823 1.366086453 0.822085045
PHOSPHO1 162466 2.151918066 0.825878994
HBG1 3047 3.750688686 0.909571271
MZB1 51237 1.577874427 0.837874386
CTLA4 1493 1.72275305 0.804868276
APOL6 80830 1.585000512 0.838162376
SLC25A39 51629 1.913617742 0.877316438
OR2W3 343171 3.255069797 0.81668837
MX1 4599 2.583429422 0.898114294
PARP9 83666 2.01914789 0.858784934
CMPK2 129607 3.000742425 0.893130822
SLC4A1 6521 4.599493665 0.929492637
ATHL1 80162 1.526619683 0.827268857
IFI44L 10964 4.743047682 0.944192627
LGALS3BP 3959 2.745738341 0.896686868
PARP12 64761 1.438693229 0.807648002
IFITM1 8519 1.186697694 0.820857959
STRADB 55437 1.978767099 0.858046179
NEAT1 283131 1.238917156 0.812869378
ETV7 51513 3.675599822 0.828771411
IFI35 3430 1.560183048 0.843283582
WARS 7453 1.125513152 0.805869979
HBB 3043 3.229330213 0.923344686
TNFSF10 8743 1.285005213 0.819643394
CCR5 1234 2.078804897 0.82739407
LAP3 51056 1.435650463 0.83985275
OTOF 9381 5.72665435 0.911098868
IFI27 3429 8.433015745 0.995079135
IRF9 10379 1.277148206 0.813758389
IFIT3 3437 4.197284404 0.933687268
TAP1 6890 1.132485754 0.80374136
HBA2 3040 4.172356065 0.943215967
OASL 8638 2.560564967 0.882412601
PATL2 197135 2.04742109 0.861765001
HES4 57801 3.421591964 0.810177301
ALAS2 212 4.929701312 0.956363318
OAS3 4940 2.605393463 0.894633377
KLHDC7B 113730 2.630618651 0.863593108
TRIM58 25893 1.802496925 0.815160773
EPB42 2038 4.945885516 0.876552639
MCOLN2 255231 2.435740185 0.801963338
BCL2L1 598 1.921406559 0.871656817
LY6E 4061 2.051243055 0.890150756
IFI6 2537 2.937837611 0.91404137
NPDC1 56654 2.301245166 0.812143143
PCSK1N 27344 4.396454608 0.890776821
LCN2 3934 2.967786287 0.888347691
GMPR 2766 2.397798552 0.851622759
ELK2AP 2003 1.583784524 0.85008264
MT1X 4501 1.177704491 0.807610438
CXCL10 3627 3.800602584 0.876540118
MIAT 440823 1.67335837 0.827444155
GBP4 115361 1.558990041 0.829222178
LTF 4057 3.920873159 0.909120505
CAMP 820 3.710881598 0.877779726
MT1E 4493 2.01353491 0.872620956
TKTL1 8277 2.766594165 0.868989783
SNCA 6622 2.79189947 0.892141641
MT2A 4502 1.433649226 0.845512371
TNFRSF17 608 2.102477288 0.813019633
RETN 56729 1.288951528 0.804505159
HBA1 3039 4.501465194 0.951567665
IFIT1 3434 4.197311662 0.928328158
DMTN 2039 1.671493185 0.842845337
DEFA1 1667 4.843900077 0.844160072
EIF2AK2 5610 1.812503548 0.83031153
AZU1 566 2.885392092 0.801475008
SLC25A37 51312 1.866656666 0.863931183
PARP14 54625 1.669917383 0.842306922
IFITM3 10410 2.238678529 0.897863869
HBM 3042 5.396215519 0.950478313
FBXO7 25793 1.124142881 0.800585996
TYMS 7298 2.473358412 0.813332666
MX2 4600 1.871766463 0.866122408
IFIT2 3433 2.904769873 0.897400581
XAF1 54739 1.817719469 0.86711159
RPS26 6231 2.508430124 0.905326555
ODF3B 440836 1.488694211 0.828621156
FCGR3B 2215 2.048695483 0.875438245
LYSMD1 388695 3.372828356 0.814672443


